Viene sostenuto il proseguimento di un’iniziativa già avviata, in collaboration with Policlinico Tor Vergata,the initial findings of which are satisfactory; it will now be developed using a more representative sample and, above all, aimed at identifying and characterizing one or more components of Lactoferrin which, at physiological concentrations in the early stages are able to prevent the infectious process (including Covid-19) to be used for the development of targeted therapeutic interventions.